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ABSTRACT
Objectives: Both total antimicrobial use and specific antimicrobials have been implicated as risk fac-
tors for healthcare-associated methicillin-resistant Staphylococcus aureus (HCA-MRSA) infection. 
The aims of this study were: (I) to explore predictors of a new HCA-MRSA infection in comparison 
with a new healthcare-associated methicillin-sensitive Staphylococcus aureus (HCA-MSSA); (II) to 
thoroughly assess the role of recent antibiotic use qualitatively and quantitatively. Methods: The 
time-period for our study was from October 1997 through September 2001. Through applying strict 
criteria, we identified two groups of inpatients, one with a new HCA-MRSA infection and one with 
a new HCA-MSSA infection. We recorded demographic, clinical and antibiotic use-related data up 
to 30 days before the positive culture date. Results: We identified 127 and 70 patients for each group, 
respectively. Two logistic regression models were carried out to assess the role of antimicrobial use 
(qualitatively and quantitatively). In model I, duration of hospital stay, presence of chronic wounds, 
aminoglycoside and fluoroquinolone use retained statistical significance. In model II, duration of 
hospital stay and history of intubation during the last month stood out as the only significant pre-
dictors of a subsequent HCA-MRSA infection. No significant differences in outcome were noted. 
Conclusions: The length of exposure to the hospital environment may be the best predictor of a new 
HCA-MRSA infection. Use of aminoglycosides and fluoroquinolones may also stand independently 
along with presence of chronic ulcers and surgical procedures. No independent association between 
quantitative antibiotic use and subsequent HCA-MRSA infection was documented. 
Keywords: methicillin-resistant Staphylococcus aureus; Staphylococcus aureus; antibacterial agents; 
fluoroquinolones.
significant risk factor for MRSA acquisition and 
infection from most, but not all, case-control 
and cohort studies.4,9-23 Both total antimicrobial 
use as well as specific antimicrobial classes 
have been implicated.11-18,24,25 Included in 
these classes are β-lactamic antibiotics,14,26-33 
cephalosporins,11,12,16,22,29 aminoglycosides,22,33,34 
macrolides,27 glycopeptides15,27-29,34 and fluoro- 
quinolones (FQs).6,11,12,14,26-29,35-37
A relatively recently published meta-analysis 
detected a clear association between exposure to 
antibiotics and MRSA isolation. Significant risk 
ratios were found for FQs, glycopeptides, cephalo-
sporins and other β-lactams.38 A prediction model, 
aimed at identifying MRSA bacteremia, predicted 
that 80% of the nosocomial bacteremias would be 
resistant to methicillin if patients had experienced 
antimicrobials prior to the onset. This model also 
indicated that there were no differences between 
antibiotics in the prediction of MRSA.29
INTRODUCTION
Methicillin-resistant Staphylococcus aureus 
(MRSA) is considered a pathogen of major im-
portance in healthcare settings.1-3 MRSA infections 
cause significant morbidity and mortality and in-
creased length of hospital stay and cost of care.4-8
Risk factors for healthcare-associated MRSA 
acquisition and infection include age, duration 
of hospitalization, underlying disease, neona-
tal or adult ICU or burn unit location, invasive 
procedures or devices, previous hospitalization, 
intensity of care, number of inter-ward transfers, 
coma, low physical function, serum albumin, 
pressure sores, immunosuppression, proximity 
to a MRSA-colonized patient, underlying der-
matological disease, enteral feedings.4,9-18
The issue of antibiotic use as a risk factor is 
complex and still not completely clarified in full 
detail. Administration of multiple antibiotics 
and multiple courses of antibiotics were a 
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The aims of the study were: (I) to explore predictors of 
a new healthcare-associated (see definition below) MRSA 
(HCA-MRSA) infection in comparison with a new healthcare 
associated MSSA (HCA-MSSA) infection; (II) to thoroughly 
assess recent antibiotic use (within the last 30 days of the posi-
tive culture date) in a qualitative as well as quantitative way 
as a possibly independent predictor of HCA-MRSA infection; 
and (III) to especially assess the role of recent FQ use.
MATERIALS AND METHODS
The Lakeside VA medical center (LSVAMC) was a 280-bed, 
tertiary-care, urban teaching hospital with approximately 
5,000 admissions per year. Computerized medical records for 
all patients admitted and followed as outpatients to LSVAMC 
were available from 1991 and thereafter. 
Our study protocol was approved by the Northwestern 
University Institutional Review Board. The time-period for 
our study was between October 1997 and September 2001. 
Inclusion and exclusion criteria
We retrospectively identified two groups of inpatients, 
one group with a new positive culture for MRSA and 
another group with a new positive MSSA culture. Patients 
with a prior history of any type of positive MRSA or MSSA 
culture up to 1991 were excluded. We considered the posi-
tive culture to be healthcare associated if (I) it was taken 
more than 48 hours after the current admission date and 
(II) if it was taken less than 48 hours after the current ad-
mission date but the patient had been hospitalized within 
the last month before the culture date.
Specimen types included in our analysis sent for 
culture for diagnostic purposes were blood, urine, sputum, 
wound, fluid and catheter tip specimens. We excluded all 
patients where SA was originally detected through active 
surveillance. Additionally, we included only those patients 
for which there were documented adequate clinical and/or 
laboratory indications for an active infection (specifically: 
a urinalysis showing pyuria and urinary symptoms for a 
urinary tract infection, an adequate sputum specimen with 
or without a positive Gram stain and respiratory symptoms 
for a respiratory tract infection, an abnormal body cavity 
fluid examination for a fluid infection, a clinically infected 
wound for a wound infection and local signs of inflammation 
and/or otherwise unexplained fever or hemodynamic 
instability for positive catheter tip cultures).
Few of the patients included in the study (18 in the MRSA 
group and 1 in the MSSA group) were outpatients on the day 
the culture was obtained. We elected not to exclude those 
patients since all of them had a history of hospitalization the 
month before the culture date, very likely to have contributed 
to the acquisition of the organism. There were eight patients 
for which both a healthcare-associated MSSA infection and a 
healthcare-associated MRSA infection were identified during 
the time-period of our study (MSSA was detected first in 8/8). 
We elected to include those cases in the MSSA group.
We used the computerized medical records of LSVAMC 
to obtain data pertinent to known risk factors for staphylo-
coccal colonization and infection. We arbitrarily considered 
events up to 30 days before the positive culture date.
We used the McCabe and Jackson classification system 
to assess the severity of underlying disease(s) and the Horn 
severity of illness index for the two groups on the day of the 
positive culture.39-40
Antibiotic data
Using the electronic pharmacy records of LSVAMC, we 
were able to obtain detailed data on intravenous antibiotic 
use (dose strength and number of doses administered) in 
our two study patient groups during the month before the 
culture date. To standardize amounts of antimicrobials ad-
ministered, we calculated defined daily doses (DDD) for 
all antibiotics. The actual antibiotic DDDs utilized for the 
purposes of our study are displayed in Table 1. 
Table 1. Definitions of defined daily doses (DDDs) of 
antibiotics studied
Antibiotic DDD
Penicillin  8 MU
Ampicillin 4 G
Piperacillin 12 G
Ampicillin/sulbactam 6 G
Ticarcillin/clavulanate 12.4 G
Piperacillin/tazobactam 13.4 G
Cefazolin 3 G
Ceftazidime 4 G
Ceftriaxone 1 G
Ceftizoxime 3 G
Aztreonam 4 G
Carbapenem 2 G
Gentamicin	 240	MG
Tobramycin	 240	MG
Amikacin 1 G
Vancomycin 2 G
Erythromycin 2 G
Metronidazole 1.5 G
Clindamycin 2.4 G
Ciprofloxacin	 800	MG
Levofloxacin	 500	MG
Trovafloxacin	 300	MG
Baraboutis, Tsagalou, Papakonstantinou et al.
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bation and presence of indwelling urinary catheter. We 
found higher rates of “other invasive procedures” in the 
HCA-MRSA group (see footnote of Table 2) but no dif-
ferences in the mean number of procedures per patient. 
Additionally, there were no significant differences in 
Horn classification at any level of severity.
Antibiotic use
Overall, significantly more HCA-MRSA patients than 
HCA-MSSA patients received at least 1, 2 or 3 different 
antibiotics. On average, HCA-MRSA were character-
ized by a significantly higher number of different anti-
biotics used than the MSSA patients (p = 0.006) and sig-
nificantly higher number of antibiotic-days (p = 0.005). 
In all subgroups with use of three or more different anti-
biotics, MRSA patients surpassed MSSA patients. Char-
acteristically, only one MSSA patient received more 
than five different antibiotics as opposed to 16 MRSA 
patients (data not shown in table).
In terms of individual antibiotic class use, all 
statistically significant differences found favored 
the HCA-MRSA group, including use of penicillins, 
aminoglycosides, lincosamides and fluoroquinolones. 
The MSSA group exhibited a non-significant trend for 
more cephalosporin use. 
Quantitative antibiotic use
Using the method of DDDs, we found significant 
differences for penicillins, fixed β-lactam/β-lactamase 
inhibitor combinations, β-lactamic antibiotics as a whole, 
aminoglycosides, glycopeptides and fluoroquinolones 
and overall quantitative antibiotic use.
Multivariate analysis
Factors and characteristics found to be significantly on 
univariate analysis were used for logistic regression analysis 
to assess independent predictors of a new HCA-MRSA 
infection. Two logistic regression models were carried out 
to assess the role of antimicrobial usage (Table 5). In the 
first one (model I) we included qualitative parameters (use 
versus no use of at least 1, 2 or 3 antibiotics and use versus no 
use of at least one member of individual antibiotic classes). 
In the second model (II), we introduced the mean number 
of different antibiotics used and antibiotic-days per patient, 
the mean number of Grams of drug administered for 
significant antibiotic classes and total grams of antibiotics 
administered per patient. In model I, duration of hospital 
stay, presence of chronic wounds, aminoglycoside and 
fluoroquinolones use retained statistical significance, while 
use of at least two different antibiotics was borderline 
significant. In model II, duration of hospital stay and 
history of intubation during the last month stood out as 
the only significant predictors of a subsequent HCA-MRSA 
infection.
Finally, we collected data about duration of hospital 
and MSICU and CCU stay for the two study groups until 
their discharge or death and we compared mortality 
rates during the current hospital stay. 
We used Version 13 of SPSS software for data 
processing, Student’s t-test for comparison of continuous 
variables and Fisher’s exact test for categorical variables. 
Logistic regression analysis (backward stepwise) was 
used to assess independent predictors of HCA-MRSA 
infections and Kaplan-Meier analysis for survival 
comparisons. A p-value of 0.05 or less was used for 
clinical significance.
RESULTS
We finally identified 127 patients with a new HCA-MRSA 
infection and 70 patients with a new HCA-MSSA infection 
eligible for further analysis. Pertinent demographic, clinical, 
laboratory and antibiotic usage data of the two groups are 
depicted on Tables 2 and 3 (characteristics significantly 
different between the two groups are shown together in 
Table 2 while those not differing significantly are gathered 
in Table 3).
Demographic and clinical data
The mean age of the MRSA group was significantly 
higher (p = 0.043). All patients were men. A small number 
of patients in both groups were nursing home residents.
Positive HCA-MSSA blood cultures represented a 
significantly higher part of the total MSSA cultures than 
HCA-MRSA (22% vs. 45.7%, p = 0.001) (Table 4).
Rates of internal medicine admission and culture 
ward were significantly higher for the HCA-MSSA 
group, while the reverse was noted for surgery wards 
without reaching statistical significance. Additionally, 
18 MRSA patients and one MSSA patient were outpa-
tients on the culture date (p = 0.002). Overall, only the 
culture ward distribution was significantly different be-
tween the two groups.
Risk factor data
Patients of the HCA-MRSA group had significantly 
higher rates of chronic decubitus ulcers while MSSA 
patients had significantly higher rates of prior 
hemodialysis. Distribution of McCabe & Jackson scoring 
was no different between the two groups.
Patients of the HCA-MRSA group had a significant-
ly longer hospital stay than the HCA-MSSA patients 
the month before the positive culture (p = 0.001). They 
also spent significantly more days in the MSICU/CCU 
(p = 0.036) even though the rates of MSICU/CCU stay and 
interward transfers did not differ between the two groups.
Patients of the HCA-MRSA group had significantly 
higher rates of surgical procedures, endotracheal intu-
Healthcare MRSA and antibiotics
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Table 2. Univariate analysis of risk factors associated with Staphylococcus aureus infections in the two study 
groups*. Characteristics found to be significantly different between the two groups
Characteristic MRSA (n = 127) MSSA (n = 70) OR and 95% CIs p
Age (years)	 71.7	±	11	 68.2	±	13	 N/A	 0.043
Culture ward§	 	 	 	 0.015 
 Internal Medicine 38 (29.9) 34 (48.6)   
	 Surgery	 47	(37.1)	 21	(30)	 	  
	 MSICU	 12	(9.4)	 7	(10)	 	  
	 CCU	 12	(9.4)	 7	(10)	 	  
 Outpatient 19 (14.9) 1 (1.4)  
Characteristic    
	 Chronic	decubitus	ulcers,	n	(%)	 55	(43.3)	 15	(21.4)	 2.13	(1.33-5.12)	 0.003
	 History	of	hemodialysis,	n	(%)	 5	(3.9)	 9	(12.9)	 0.28	(0.09-0.86)	 0.027
 Hospital stay    
	 	 Days	of	hospital	stay	(mean	±	SD)	 18	±	9	 9	±	6.8	 1.134	(1.086-1.184)	 0.001
	 	 Days	of	MSICU/CCU	stay	(mean	±	SD)		 6.4	±	6	 3.6	±	4.4	 1.123	(1.002-1.258)	 0.046
 Other invasive procedure, n (%)¶	 17	(13.4)	 2	(2.9)	 5.25	(1.17-23.45)	 0.03
 Surgery, n (%)||	 44	(34.6)	 13	(18.6)	 2.32	(1.15-4.70)	 0.019
	 Endotracheal	intubation,	n	(%)	 48	(37.8)	 13	(18.6)	 1.66	(1.32-5.71)	 0.006
	 Indwelling	urinary	catheter	>24	hours,	n	(%)	 105	(82.7)	 41	(58.6)	 3.376	(1.74-6.54)	 0.001
	 At	least	1	antibiotic	used	 100	(78.7)	 40	(57.1)	 2.78	(1.47-5.25)	 0.002
	 At	least	2	antibiotics	used	 66	(51.96)	 19	(27.1)	 2.904	(1.55-5.46)	 0.001
	 At	least	3	antibiotics	used	 46	(36.2)	 9	(12.8)	 3.85	(1.75-8.46)	 0.001
	 Number	of	antibiotics	used/patient	(mean	±	SD)	 2.6	±	1.7	 1.8	±	1.2	 1.49	(1.10-2.01)	 0.009
	 Antibiotic-days/patient	(mean	±	SD)	 5.17	±	6.0	 1.89	±	3.6	 1.19	(1.08-1.30)	 0.005
	 Penicillins,	n	(%)	 65	(51.2)	 22	(31.4)	 2.28	(1.24-4.22)	 0.008
	 Aminoglycosides,	n	(%)	 41	(32.3)	 9	(12.9)	 3.23	(1.46-7.14)	 0.004
	 Lincosamides,	n	(%)	 21	(16.5)		 2	(2.9)	 6.74	(1.53-29.65)	 0.012
	 Fluoroquinolones,	n	(%)	 39	(30.7)	 7	(10)	 3.99	(1.67-9.49)	 0.002
Mean DDDs per patient for antibiotic  
classes (mean ± SD) **    
	 Penicillins	 5.5	±	8.1	 2.0	±	4.5	 1.10	(1.03-1.17)	 0.002
 Fixed β-lactam/β-lactamase  
	 inhibitor	combinations	 4.5	±	7.6	 1.9	±	4.6	 1.08	(1.01-1.14)	 0.015
 β-	Lactamic	antibiotics	 7.3	±	9.4	 2.5	±	4.7	 1.11	(1.05-1.17)	 0.001
	 Aminoglycosides	 1.9	±	4.3	 0.4	±	1.3	 1.31	(1.06-1.61)	 0.011
	 Glycopeptides	 5.2	±	5.1	 0.9	±	0.5	 5.15	(3.31-19.92)	 0.017
	 Fluoroquinolones		 2	±	4.3	 0.4	±	1.5	 1.27	(1.06-1.51)	 0.008
 All classes of	antibiotics	 25.12	±	28.7	 7.82	±	14.21	 1.042	(1.02-1.06)	 0.001
*All	 parameters	 were	 assessed	 and	measured	 for	 the	 month	 (last	 30	 days)	 before	 the	 positive	 culture	 date;	 § the ward of pa-
tient residence at the date of the positive culture; ¶ procedures performed by medicine house staff (bone marrow biopsies, ar-
throcenteses etc); || includes procedures performed by the surgical team in the operating room and (rarely) at bedside; ** defined 
daily dose (grams or milligrams of the antibiotic an average person would usually receive in a day, e.g. 2 g for vancomycin). 
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; OR, odds ratio; CI, confidence 
intervals; N/A, not applicable; MSICU, medical/surgical intensive care unit; CCU, coronary care unit; SD, standard deviation.
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Table 3. Univariate analysis of risk factors associated with Staphylococcus aureus infections in the two study 
groups*. Characteristics found not to be significantly different between the two groups
Characteristic MRSA (n = 127) MSSA (n = 70) OR and 95% CIs p
Sex (male/female)	 127/0	 70/0	 N/A	 1.000
Nursing home resident (n/%)	 10	(7.8)	 2	(2.8)	 0.34	(0.073-1.62)	 0.18
Admission ward §	 	 	 	 0.146
 Internal Medicine 42 (33.1) 38 (54.3)  
 Surgery 55 (43.3) 22 (31.4)  
 MSICU 6 (4.7) 6 (8.6)  
 CCU 4 (3.1) 3 (4.3)  
Characteristic    
	 Coma	>	24	hours,	n	(%)	 16	(12.6)	 5	(7.1)	 1.87	(0.65-5.35)	 0.24
	 Diabetes	mellitus,	n	(%)	 57	(44.9)	 25	(35.7)	 1.46	(0.80-2.67)	 0.21
	 End-stage	renal	disease,	n	(%)	 7	(5.5)	 8	(11.4)	 0.45	(0.16-1.3)	 0.14
	 Immunosuppression,	n	(%)**	 24	(18.9)	 15	(21.4)	 0.85	(0.41-1.76)	 0.67
 Preexisting permanent central  
	 venous	catheter,	n	(%)	 13	(10.2)	 12	(17.1)	 1.81	(0.78-4.23)	 0.183
	 McCabe	score	 	 	 	 0.203
  NF, n (%) 68 (53.3) 44 (62.9)  
  UF, n (%) 58 (45.7) 24 (34.3)  
	 	 RF,	n	(%)	 1	(0.8)	 2	(2.8)	 	
 Hospital stay    
	 Rates	of	MSICU/CCU	stay	(%)	 38.6	 42.9	 0.838	(0.46-1.51)	 0.649
	 Patient	rates	with	at	least	1	interward	transfer	(%)	 55.9%	 50%	 0.79	(0.44-1.42)	 0.458
	 ≥	2	transfers	 23.1%	 22.1%	 1.064	(0.52-2.17)	 0.86
	 ≥	3	transfers	 8.7%	 2.9%	 3.22	(0.69-14.98)	 0.135
	 Paracentesis,	n	(%)	 12	(9.4)	 6	(8.6)	 1.11	(0.40-3.1)	 0.838
	 Bronchoscopy,	n	(%)	 3	(2.4)	 1	(1.4)	 1.67	(0.17-16.36)	 0.657
	 Gastrointestinal	endoscopy,	n	(%)	 19	(15.0)	 13	(18.6)	 0.77	(0.35-1.67)	 0.511
	 Angiography,	n	(%)	 11	(8.7)	 3	(4.3)	 2.12	(0.57-7.86)	 0.253
 Mean number of procedures  
 per patient (mean ± SD)¶¶	 0.53	±	0.66	 0.49	±	0.58	 1.11	(0.69-1.76)	 0.32
	 Mechanical	ventilation	>	24	hours,	n	(%)	 26	(20.5)	 9	(12.9)	 1.74	(0.76-3.97)	 0.181
	 Nasogastric	tube	>	24	hours,	n	(%)	 53	(41.7)	 20	(28.6)	 1.79	(0.95-3.35)	 0.067
	 Enteral	feedings	>	24	hours,	n	(%)	 10	(7.9)	 7	(10)	 0.66	(0.25-1.76)	 0.410
	 Drainage	tube	>	24	hours,	n	(%)	 18	(14.2)	 8	(11.4)	 1.28	(0.53-3.11)	 0.586
	 Presence	of	central	venous	catheter	in-house,	n	(%)	 56	(44.1)	 24	(34.3)	 1.51	(0.82-2.77)	 0.180
	 Horn	classification	 	 	 	 0.581
	 	 1,	n	(%)	 4	(3.1)	 0	(0)	 	
  2, n (%) 61 (48) 29 (41.4)  
  3, n (%) 47 (37) 34 (48.6)  
	 	 4,	n	(%)	 15	(11.8)	 7	(10)	 	
	 Cephalosporins,	n	(%)	 18	(14.2)	 17	(24.3)	 0.55	(0.26-1.14)	 0.108
cont.
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Table 3. Univariate analysis of risk factors associated with Staphylococcus aureus infections in the two study 
groups*. Characteristics found not to be significantly different between the two groups (Cont.)
Characteristic MRSA (n = 127) MSSA (n = 70) OR and 95% CIs p
 Fixed β-lactam/β-lactamase inhibitor combinations, n (%) 43 (33.9) 17 (24.3) 1.59 (0.82-3.08) 0.162
 β-Lactamic antibiotics, n (%) 80 (63) 36 (51.4) 1.61 (0.89-2.90) 0.115
 Glycopeptides, n (%) 32 (25.2)  11 (15.7) 1.81 (0.85-3.85) 0.123
 Macrolides, n (%) 67 (5.5) 1 (1.4) 4.02 (0.48-33.40) 0.197
 Nitroimidazoles, n (%) 7 (5.5) 0 (0.0) -- 0.99
Mean DDDs per patient for antibiotic classes (mean ± SD) || ||    
 Cephalosporins 1.0 ± 3.2 0.3 ± 0.9 1.15 (0.97-1.38) 0.111
 Macrolides 3.3 ± 3 1 1.72 (0.43-6.99) 0.445
 Lincosamides 4.9 ± 4 5.8 ± 3.4 0.95 (0.66-1.35) 0.765
 Nitroimidazoles 7.7 ± 5.7 0 -- 0.99
*All parameters were assessed and measured for the month (last 30 days) before the positive culture date; § the initial admission ward 
during the hospitalization where the new infection was noted; ** corticosteroid use of at least 7.5 mg prednisone daily or equivalent, cy-
totoxic chemotherapy or other potent immunosuppressive agents, whole-body radiation or presence of human immunodeficiency virus 
infection; ¶¶ mean number of procedures: the sum of paracenteses, bronchoscopies, gastrointestinal endoscopies, angiographies, hemo-
dialysis sessions, central line placement during current admission and other invasive procedures (hemodialysis sessions were counted as 
1 procedure); || || defined daily dose.
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; OR, odds ratio; CI, confi-
dence intervals; N/A, not applicable; MSICU, medical/surgical intensive care unit; CCU, coronary care unit; NF, non-fatal illness; 
UF, ultimately fatal; RF, rapidly fatal; SD, standard deviation.
Table 4. Distribution of culture specimens in the two study groups
Type of culture specimen MRSA MSSA p
Blood, n (%) 28 (22) 32 (45.7) 0.001
Urine, n (%) 26 (20.5) 8 (11.4) 0.119
Sputum, n (%) 23 (18.1) 9 (12.9) 0.421
Other fluid, n (%) 6 (4.7) 8 (11.4) 0.090
Wound drainage fluid, n (%) 45 (35.4) 16 (22.9) 0.078
CVC tip, n(%) 3 (2.4) 4 (5.7) 0.248
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; CVC, central venous cath-
eter. Note that cumulative numbers and percentages of culture specimens may exceed the number of patients and 100 respec-
tively, since some patients had positive cultures from more than one site on the culture date.
Table 5. Predictors of healthcare associated methicillin-resistant Staphylococcus aureus infections by logistic 
regression analysis [backward stepwise (Wald)]
Model  Variable OR & 95% CI p
 Duration of hospital stay 1.163 (1.059-1.278) 0.002
I (qualitative indices
 Chronic ulcers 0.203 (0.044- 0.944) 0.042
of antibiotic exposure only)
 Aminoglycosides 11.123 (1.70-72.73) 0.012
 Fluroquinolones 7.74 (1.26-47.32) 0.027
 (Use of at least 2 different antibiotics) [0.168 (0.027-1.038)] (0.055)
II (quantitative indices 
of antibiotic exposure only) 
Duration of hospital stay 1.18 (1.077- 1.293) 0.000
 
Intubation 5.56 (1.37-22.50) 0.016
Baraboutis, Tsagalou, Papakonstantinou et al.
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Analysis of outcomes
We performed comparative analysis of several outcome 
indicators between the two study groups (Table 6). A 
relatively higher percentage of MSSA patients spent 
time in the MSICU/CCU after the positive culture date 
but the MRSA group showed a trend for more days of 
MSICU/CCU stay on average. No difference in survival 
was observed (Figure 1).
DISCUSSION
We were able to demonstrate that, in our study population, 
significant predictors of a new HCA-MRSA infection as op-
posed to a new HCA-MSSA infection were the duration of 
recent hospital stay, presence of chronic wounds, history of in-
tubation and use of any aminoglycoside and fluoroquinolone. 
The findings of our study are in significant agreement with 
similar studies. However, there are, in our opinion, some in-
teresting features arisen from our analysis that worth further 
discussion.
In our study, MRSA patients were older than the 
MSSA patients, which has been the case in some but not all 
studies.9,27,28 Additionally, the MRSA group seemed to be dif-
ferent from the MSSA group in certain parameters. The MRSA 
group consisted of a preponderance of “surgical” patients 
while the MSSA group of mostly “internal medicine” patients. 
Accordingly, the MRSA patients had significantly higher 
rates of surgery during the current admission and also higher 
rates of endotracheal intubation but not prolonged mechani-
cal ventilation, indicating elective intubation for surgery. The 
MRSA group had clearly spent more days in-hospital and 
more days in the MSICU/CCU before the culture date, a dif-
ference frequently found in similar studies.9,28 Additionally, 
the MRSA patients had higher rates of decubitus ulcers and 
presence of indwelling urinary catheter for more than 24 
hours, both known risk factors for MRSA colonization and 
infection.28 On the other hand, the MSSA group included a 
higher percentage of chronic hemodialysis patients.
Antibiotic use
Overall, the MRSA group was characterized by significantly 
heavier antibiotic use than the MSSA group by all types of 
analyses we performed. The mean number of antibiotics used 
per patient differed significantly, while the mean antibiotic-
days were at least two-fold for the MRSA group.
By the two types of logistic regression analysis we per-
formed, we were able to show that recent exposure, in a qualita-
tive way, to aminoglycosides and fluoroquinolones stood out 
as independent indicators of a subsequent HCA-MRSA infec-
tion. These results are in agreement with prior studies, looking 
at qualitative use of those antibiotics.6,11,12,14,22,26-29,33-38 Addition-
ally, use of at least two different antibiotics during the previous 
month was at the border of statistical significance. The under-
lying mechanisms have not been completely clarified but sev-
eral lines of evidence exist. Fluoroquinolones, for example, are 
excreted in apocrine and eccrine sweat of healthy individuals 
Table 6. Outcome analysis for the two study groups
Hospital stay (after the positive culture date) MRSA (n = 127) MSSA (n = 70) p
Duration	of	hospital	stay	(days)	 21	±	21	 19	±	20	 0.467
MSICU/CCU	stay,	n,%	 23	(18.1)	 19	(27.1)	 0.138
Duration	of	MSICU/CCU	stay	(days)	 31	±	26	 18	±	21	 0.081
Mortality	during	current	hospital	stay,	n(%)	 26	(20.5)	 14	(20)	 0.937
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; MSICU, medical-surgical 
intensive care unit; CCU, coronary care unit.
Figure 1: Comparative analysis of survival during current 
admission between the two groups.
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, 
methicillin-sensitive Staphylococcus aureus.
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of our data. The LSVAMC population, form which the study 
groups derived, was largely homogeneous (exclusively males 
with similar patterns of comorbidities) and also relatively sta-
ble in the sense that those patients would seldom be admitted 
in another institution and, if so, this would be one out of the 
other VA hospitals of the Chicago area. Since the computerized 
filing system was common to all Chicago VA hospitals, such 
information was readily available. The same held true for out-
patient visits. The strict criteria used may be more important 
for the HCA-MSSA group. Rates of methicillin-resistance in 
hospitalized patients are increasing worldwide, so that creating 
this specific kind of patient groups is becoming more and more 
difficult.
Despite the existence of complete records about intrave-
nous antibiotics for inpatients and outpatients, that was not the 
case with inpatient or outpatient oral antibiotics. Nevertheless, 
it is safe to say, at least in regards to inpatient oral antibiotic 
therapy, that the volume of the oral therapy was relatively small 
compared to its intravenous counterpart for the great major-
ity of hospitalized patients at the LSVAMC, even for antibiotics 
with excellent oral bioavailability like the fluoroquinolones.
Additionally, we designed this study electing to “look back” 
at the last 30 days before the positive culture date, this way cre-
ating a fixed period of exposure to risk factors (or time at risk) 
for the two groups. Previous studies of HCA-MRSA infections 
may have not adjusted enough for differences in time at risk.
Besides qualitative information about antibiotic use, we 
also had accurate quantitative data in our disposition. The fact 
that quantitative indices of antibiotic use did not emerge as in-
dependent predictor of a subsequent HCA-MRSA infection 
does not abrogate the clear-cut heavier antibiotic exposure of 
the MRSA group. This observation along with the preponder-
ance of “surgical” patients in the MRSA group may have im-
mediate real-life implications. The use of antimicrobial agents 
in hospitals in the US and several European countries is often 
excessive or unnecessary.50 The problem may be augmented in 
surgical subspecialty clinics, where antibiotic “coverage” may 
be used to provide a sense of safety and awareness of adverse 
consequences of prolonged use and efforts for rational use are 
less well established. 
There were several limitations in our study. We did not in-
clude a third uninfected group for comparison purposes.28,44 Even 
though such a control group has frequently not been included 
in similar studies, it would certainly have made our observations 
more widely valid. Due to inadequate data, we were not able to 
calculate and compare device-days (catheter-days, etc). Finally, 
hospital cost data about the two groups were not available.
CONCLUSION
Length of exposure to the hospital environment may be 
the best predictor of a new HCA-MRSA infection. Use of 
aminoglycosides and fluoroquinolones may also stand 
independently along with presence of chronic ulcers 
undergoing antibiotic therapy and could promote the acqui-
sition of MRSA by eradicating susceptible microorganisms 
such as MSSA.41 Subinhibitory concentrations of ciprofloxa-
cin induced the production of fibronectin-binding proteins 
and increased the adhesion to fibronectin-coated surfaces in 
vitro, promoting host colonization.42 Fluoroquinolones might 
influence oxacillin resistance by selective inhibition or by kill-
ing of the more susceptible subpopulations in heteroresistant 
S. aureus.43 In our study, 120/127 (94.49%) and 122/127 (96.1%) 
of the MRSA strains had intermediate sensitivity or frank resist-
ance to at least one member of the fluoroquinolone and amino-
glycoside classes respectively, while the respective numbers for 
the MSSA group were 32/70 (45.71%) and 44/70 (62.85%) (data 
not shown in table).
A lesser number of studies has evaluated the role of anti-
biotics quantitatively.25,28,44 In our study, even though quantita-
tive use of several antibiotic classes and antibiotics as a whole 
was much heavier in the MRSA group, no quantitative index 
emerged as independent predictor of HCA-MRSA infections. 
Graffunder et al showed that quantitative use of levofloxacin 
was independently associated with MRSA infection.27 Ernst 
et al, using a case-case-control study design, found significant 
qualitative and quantitative differences in fluoroquinolone use 
between the MRSA and MSSA bacteremia groups but not be-
tween the MRSA and the uninfected group.44 In our study, the 
role of antibiotics was surpassed by the effect of length of ex-
posure to the hospital environment and surgical procedures, 
as represented by the history of intubation. These two fac-
tors, especially the former, are, without any doubt, among the 
strongest predictors of MRSA infections in older and newer 
studies.4,9-18,20-23,25-28,33,34 Obviously, differences in our results 
compared to the above-described studies may be partly due to 
different study design and differences in populations studied, 
as noted in a recent meta-analysis.38 Additionally, from a su-
banalysis of the blood isolates of our study groups, the mean 
number of antibiotic-days did emerge as independent predictor 
of a subsequent HCA-MRSA bacteremia.45
Outcome analysis
No significant differences in morbidity or mortality were 
found (Table 6). Studies especially focusing on morbidity dif-
ferences are limited, while the impact of methicillin resistance 
on mortality has been extensively studied for SA bacteremia 
and several- but not all- studies, including two meta-analyses, 
have reported a real effect.27,46-49 A main reason for this appar-
ent disagreement may be a case-mix effect due to the variety of 
SA infections included in our study groups and this attenuation 
phenomenon has also been noted elsewhere.18 Another reason 
may be the significantly higher percentage of bloodstream in-
fections in the MSSA group.
Strengths and limitations of the study
We used strict inclusion and exclusion criteria to create our 
study groups, empowered by the major degree of completeness 
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and exposure to surgical procedures. No independent asso-
ciation between quantitative antibiotic use with the method 
of DDDs and subsequent HCA-MRSA infection was docu-
mented. Efforts for minimized and well-targeted patient stay 
in-hospital along with rational use of antibiotics by physi-
cians of all subspecialties represent both immediate needs 
and important indices of quality of medical care.
REFERENCES
1.  Horan TC, White JW, Jarvis WR et al. Nosocomial infection 
surveillance, 1984. MMWR 1986; 35: 17SS-29SS.
2.  Preheim LC, Rimland D, Bittner MJ. Methicillin-resistant 
Staphylococcus aureus in Veterans Administration Medical 
Centers. Infect Control 1987 May; 8(5): 191-4.
3.  Wakefield DS, Pfaller M, Massanari RM et al. Variation in 
methicillin-resistant Staphylococcus aureus occurrence by ge-
ographic location and hospital characteristics. Infect Control 
1987 Apr; 8(4): 151-7.
4.  Onorato M, Borucki MJ, Baillargeon G et al. Risk factors 
for colonization or infection due to methicillin-resistant 
Staphylococcus aureus in HIV-positive patients: a retrospec-
tive case-control study. Infect Control Hosp Epidemiol 1999 
Jan;20(1): 26-30.
5.  Crane LR, Levine DP, Zervos MJ, Cummings G. Bacteremia 
in narcotic addicts at the Detroit Medical Center. I. Micro-
biology, epidemiology, risk factors and empiric therapy. Rev 
Infect Dis 1986 May-June; 8(3): 364-73.
6.  Campillo B, Dypeyron C, Richardet JP. Epidemiology of 
hospital-acquired infections in cirrhotic patients: effect of 
carriage of methicillin-resistant Staphylococcus aureus and 
influence of previous antibiotic therapy and norfloxacin 
prophylaxis. Epidemiol Infect 2001 Dec; 127(3): 443-50.
7.  Herwaldt LA. Control of methicillin-resistant Staphylococcus 
aureus in the hospital setting. Am J Med 1999 May; 106 (5A): 
11S-18S.
8.  Abramson MA, Sexton DJ. Nosocomial methicillin-resistant 
and methicillin-susceptible Staphylococcus aureus primary 
bacteremia: at what costs? Infect Control Hosp Epidemiol 
1999 Jun; 20(6): 408-11.
9.  Sadoyama G, Filho PPG. Risk factors for methicillin-resistant 
and sensitive Staphylococcus aureus in a Brazilian University 
hospital. Braz J Infect Dis 2000 Jun; 4(3): 135-43.
10.  O’ Sullivan NP, Keane CT. Risk factors for colonization with 
methicillin-resistant Staphylococcus aureus among nursing 
home residents. J Hosp Infect 2000 Jul; 45(3): 206-10.
11.  Asensio A, Guerrero A, Quereda C, Lizan M, Martinez-Fer-
rer M. Colonisation and infection with methicillin-resistant 
Staphylococcus aureus: Associated factors and eradication. 
Infect Control Hosp Epidemiol 1996 Jan; 17(1): 20-8.
12.  Crowcroft N, Maguire H, Fleming M, Peacock J, Thomas J. 
Methicillin-resistant Staphylococcus aureus: Investigation of 
a hospital outbreak using a case-control study. J Hosp Infect 
1996 Dec; 34(4): 301-9.
13.  Law MR, Gill ON. Hospital-acquired infection with methicillin-
resistant and methicillin-sensitive staphylococci. Epidemiol In-
fect 1988 Dec; 101(3): 623-9.
14.  Dziekan G, Hahn A, Thune K et al. Methicillin-resistant Staphy-
lococcus aureus in a teaching hospital: Investigation of nosoco-
mial transmission using a matched case-control study. J Hosp 
Infect 2000 Dec; 46(4): 263-70.
15.  Coll PP, Crabtree BF, O’Conner PJ. Clinical risk factors for 
methicillin-resistant Staphylococcus aureus bacteriuria in a 
skilled-care nursing home. Arch Fam Med 1994 Apr; 3(4): 
357-60.
16.  Washio M, Mizoue T, Kajioka T et al. Risk factors for methi-
cillin-resistant Staphylococcus aureus (MRSA) infection in a 
Japanese elderly care nursing home. Public Health 1997 May; 
111(3): 187-90.
17.  Warshawsky B, Hussain Z, Gregson DB et al. Hospital- and 
community-based surveillance of methicillin-resistant 
Staphylococcus aureus: Previous hospitalization is the major 
risk factor. Infect Control Hosp Epidemiol 2000 Nov; 21911): 
724-7.
18.  Hershow RC, Khayr WE, Smith NL. A comparison of clini-
cal virulence of nosocomially acquired methicillin-resistant 
and methicillin-sensitive Staphylococcus aureus infections in a 
University hospital. Infect Control Hosp Epidemiol 1992 Oct; 
13(10): 587-93.
19.  Santoro-Lopes G, de Gouvea EF, Monteiro RC et al. Coloniza-
tion with methicillin-resistant Staphylococcus aureus after liver 
transplantation. Liver Transpl 2005 Feb; 11(2): 203-9.
20.  Yee-Lean L, Gupta G, Cesario T et al. Colonisation by Staphy-
lococcus aureus resistant to methicillin and ciprofloxacin dur-
ing 20 months’ surveillance in a private skilled nursing facility. 
Infect Control Hosp Epidemiol 1996 Oct; 17(10): 649-53.
21.  Boyce JM, Landry M, Deetz TR, DuPont HL. Epidemiologic 
studies of an outbreak of nosocomial methicillin-resistant 
Staphylococcus aureus infections. Infect Control 1981 Mar-
Apr; 2(2) : 110-6.
22.  Peacock JE, Marsik FJ, Wenzel RP. Methicillin-resistant Staph-
ylococcus aureus : Introduction and spread within a hospital. 
Ann Intern Med 1980 Oct; 93(4): 526-32.
23.  Crossley K, Loesch D, Landesman B et al. An outbreak of in-
fections caused by strains of Staphylococcus aureus resistant to 
methicillin and aminoglycosides. I. Epidemiologic studies. J 
Infect Dis 1979 Mar;139(3): 280-7.
24.  Thompson RL, Cabezudo I, Wenzel RP. Epidemiology of noso-
comial infections caused by methicillin-resistant Staphylococ-
cus aureus. Ann Intern Med 1982 Sep; 97(3): 309-17.
25.  Harbarth S, Rutschmann O, Sudre P, Pittet D. Impact of me-
thicillin resistance on the outcome of patients with bacteremia 
caused by Staphylococcus aureus. Arch Intern Med 1998 Jan; 
158(2): 182-9.
26.  Hori S, Sunley R, Tami A, Grundmann H. The Nottingham 
Staphylococcus aureus population study: prevalence of MRSA 
among the elderly in a university hospital. J Hosp Infect 2002 
Jan; 50(1):25-9.
27.  Graffunder EM, Venezia RA. Risk factors associated with no-
socomial methicillin-resistant Staphylococcus aureus (MRSA) 
infection including previous use of antimicrobials. J Antimi-
crob Chemother 2002 Jun; 49(6): 999-1005.
28. Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y. 
Fluoroquinolones and the risk for methicillin-resistant Staphy-
lococcus aureus in hospitalized patients. Emerg Infect Dis 2003 
Nov; 9(11): 1415-22.
29. Lodise TP, Jr, McKinnon PS, Rybak M. Prediction model to 
identify patients with Staphylococcus aureus bacteremia at risk 
for methicillin resistance. Infect Control Hosp Epidemiol 2003 
Sep; 24(9): 655-61.
30. Baggett HC, Hennessy TW, Rudolph K et al. Community-on-
set methicillin-resistant Staphylococcus aureus associated with 
antibiotic use and the cytotoxin Panton-Valentine leukocidin 
during a furunculosis outbreak in rural Alaska. J Infect Dis 
2004 May 1; 189(9): 1565-73.
Healthcare MRSA and antibiotics
BJID-5-agosto.indd   434 27/09/11   09:59
435Braz J Infect Dis 2011; 15(5):426-435
31. Garcia-Vazquez E, Gomez J, Banos R et al. A comparative 
study of patients with methicillin susceptible versus methicil-
lin resistant Staphylococcus aureus bacteremia: epidemiology 
and prognostic factors. Med Clin (Barc) 2007 May 12; 128(18): 
681-6.
32. Tumbarello M, de Gaetano Donati K, Tacconelli E et al. Risk 
factors and predictors of mortality of methicillin-resistant 
Staphylococcus aureus (MRSA) bacteraemia in HIV-infected 
patients. J Antimicrob Chemother 2002 Sep; 50(3): 375-82.
33.  Ward TT, Winn RE, Hartstein AL, Sewell DL. Observations relat-
ing to an inter-hospital outbreak of methicillin-resistant Staphylo-
coccus aureus: Role of antimicrobial therapy in infection control. 
Infect Control 1981 Nov-Dec; 2(6): 453-9.
34.  Asensio A, Guerrero A, Quereda C, Lizan M, Martinez-Fer-
rer M. Colonisation and infection with methicillin-resistant 
Staphylococcus aureus: Associated factors and eradication. In-
fect Control Hosp Epidemiol 1996 Jan; 17(1): 20-8.
35.  Tacconelli E, Venkataraman L, De Girolami PC, D’Agata EM. 
Methicillin-resistant Staphylococcus aureus bacteraemia diag-
nosed at hospital admission: distinguishing between commu-
nity-acquired versus healthcare-associated strains. J Antimi-
crob Chemother 2004 Mar; 53(3): 474-9.
36.  Santoro-Lopes G, de Gouvea EF, Monteiro RC et al. Coloniza-
tion with methicillin-resistant Staphylococcus aureus after liver 
transplantation. Liver Transpl 2005 Feb; 11(2): 203-9.
37.  Zahar JR, Clec’h C, Tafflet M et al. Is methicillin resistance 
associated with a worse prognosis in Staphylococcus aureus 
ventilator-associated pneumonia? Clin Infect Dis 2005 Nov 1; 
41(9): 1224-31.
38.  Tacconelli E, De Angelis G, Cataldo MA, Pozzi E, Cauda R. Does 
antibiotic exposure increases the risk of methicillin-resistant 
Staphylococcus aureus (MRSA) isolation? A systematic review and 
meta-analysis. J Antimicrob Chemother 2008: 61: 26-38. 
39.  McCabe WR, Jackson GG. Gram-negative bacteremia (I. Eti-
ology and ecology). Arch Intern Med 1962 Dec; 110: 83-91.
40.  Mc Cabe WR, Jackson GG. Gram-negative bacteremia (II. 
Clinical, laboratory and therapeutic observations). Arch In-
tern Med 1962 Dec; 110: 92-100.
41.  Hoiby N, Jarlov JO, Kemp M et al. Excretion of ciprofloxacin in 
sweat and multiresistant Staphylococcus epidermidis. Lancet 1997 
Jan 18; 349(9046):167-9.
42.  Bisognano C, Vaudaux PE, Lew DP, Ng EY, Hooper DC. In-
creased expression of fibronectin-binding proteins by fluoro-
quinolone-resistant Staphylococcus aureus exposed to subin-
hibitory levels of ciprofloxacin. Antimicrob Agents Chemother 
1997 May; 41(5): 906-13.
43.  Venezia RA, Domaracki BE, Evans AM, Preston KE, Graf-
funder EM. Selection of high-level oxacillin resistance in het-
eroresistant Staphylococcus aureus by fluoroquinolone expo-
sure. J Antimicrob Chemother 2001 Sep; 48(3): 375-81.
44.  Ernst EJ, Raley G, Herwaldt LA, Diekema DJ. Importance of 
control group selection for evaluating antimicrobial use as a risk 
factor for methicillin-resistant Staphylococcus aureus bactere-
mia. Infect Control Hosp Epidemiol 2005 Jul; 26(7): 634-7.
45. Baraboutis IG, Tsagalou EP, Skoutelis AT et al. Predictors of 
methicillin resistance in healthcare-associated Staphylococcus 
aureus bloodstream infections: the role of recent antibiotic 
use. J Chemother 2010 Dec;22(6):424-7. 
46.  Soriano A, Martinez JA, Mensa J et al. Pathogenic significance 
of methicillin resistance for patients with Staphylococcus au-
reus bacteremia. Clin Infect Dis 2000 Feb; 30(2): 368-73.
47.  Topeli A, Unal S, Akalin HE. Risk factors influencing clinical out-
come in Staphylococcus aureus bacteraemia in a Turkish University 
Hospital. Int J Antimicrob Agents 2000 Feb; 14(1): 57-63.
48.  Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, 
Karchmer AW, Carmeli Y. Comparison of mortality associated 
with methicillin-resistant and methicillin-susceptible Staphy-
lococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 
2003 Mar 1;36(5):592-8. Epub 2003 Feb 7.
49.  Whitby M, McLaws ML, Berry G. Risk of death from methicil-
lin-resistant Staphylococcus aureus bacteraemia: a meta-analy-
sis. Med J Aust 2001 Sep 3;175(5):264-7.
50.  Muto CA, Jernigan JA, Ostrowsky BE et al. SHEA guideline for 
preventing nosocomial transmission of multidrug-resistant 
strains of Staphylococcus aureus and enterococcus. Infect Con-
trol Hosp Epidemiol 2003 May; 24(5): 362-86.
Baraboutis, Tsagalou, Papakonstantinou et al.
BJID-5-agosto.indd   435 27/09/11   09:59
